Sonnet Biotherapeutics Falls Despite Merger Approval

Sonnet Biotherapeutics Holdings Inc's stock dropped 48.39%, hitting a 20-day low. This decline occurred despite shareholders approving a merger with Hyperliquid Strategies Inc, a significant step in the company's strategic transformation.

The merger is expected to enhance Sonnet's competitiveness in the oncology biopharmaceutical sector, leveraging its FHAB technology to improve drug safety and efficacy. Following the merger, Sonnet plans to list on Nasdaq, which could increase its visibility and access to capital markets.

This development raises questions about market sentiment towards the biotech sector, especially given the broader market context where the Nasdaq-100 is up slightly while the S&P 500 is down. Investors may be cautious about the execution of the merger and its potential impact on Sonnet's future performance.